ストックスクリーナーアプリを入手
2.56
1.54%
-0.04
アフターアワーズ：
2.56
Cellectar Biosciences Inc (CLRB) 最新ニュース
Cellectar Biosciences Inc (CLRB) (Q2 2026) Earnings Call Highlig - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Cellectar Biosciences (CLRB): Caligan Partners reports 5.9% ownership stake - Stock Titan
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Cellectar’s New Phase 3 WM Trial Puts Iopofosine I 131 on Investors’ Radar - TipRanks
Cellectar Biosciences (CLRB) investor discloses 9.99% stake and warrant holdings - Stock Titan
Cellectar Biosciences (CLRB) investor discloses 9.99% stake via stock and warrants - Stock Titan
Cellectar Biosciences Inc (CLRB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Balyasny Asset Management (CLRB) discloses 9.99% Cellectar stake via stock and warrants - Stock Titan
Cellectar Biosciences, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Cellectar Biosciences (CLRB) ownership: Bleichroeder group reports 9.99% equity stake - Stock Titan
Cellectar Biosciences Releases Q2 2026 Financial Results - AlphaStreet
Earnings call transcript: Cellectar narrows focus on WM as Q2 2026 loss widens - Investing.com
CLRB: Positive clinical results, robust financing, and regulatory momentum drive pipeline advancement - TradingView
Cellectar Biosciences Q2 2026 Earnings Call Transcript - benzinga.com
Cellectar Q2 net loss widens 28% to $6.9M, misses EPS estimate - scanx.trade
Cellectar Biosciences reports Q2 2026 net loss $6.9M, cash $34.0M; advances iopofosine Phase 3 - TradingView
CLRB: Strong clinical progress and financing position support upcoming NDA submission in WM - TradingView
Cellectar Biosciences (CLRB) Q2 loss hits $6.9M as cash reaches $34M - Stock Titan
Cellectar Biosciences Q2 net loss widens on higher R&D costs - TradingView
Cellectar Prepares ~100-Patient-Per-Arm Trial, Plans 2027 FDA Filing - Stock Titan
Cellectar Biosciences 6M 2026: Net loss $(12.6M), Diluted EPS $(1.52) — 10-Q Summary - TradingView
Cellectar Biosciences (CLRB) raises $31.7M, flags going concern risk - Stock Titan
Cellectar Biosciences (CLRB) Earnings Date and Reports 2026 $CLRB - MarketBeat
Cellectar Biosciences Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Empery Asset Management, LP Initiates Position in Cellectar Bios - GuruFocus
Cellectar Biosciences Sets Major Conference Schedule: Pediatric Cancer Data Featured - Stock Titan
Cellectar Biosciences (CLRB) Sets Q3 2024 Earnings Call for Nov 18 - Stock Titan
Cellectar BioSciences (CLRB.US) will release its earnings report before the market opens on August 13. - Moomoo
Empery Asset Management (CLRB) discloses 9.99% beneficial stake via stock and warrants - Stock Titan
Cellectar Biosciences to Report Second Quarter Financial - GlobeNewswire
Cellectar Biosciences to Report Second Quarter 2026 Financial Results and Provide Corporate Update on August 13 - Quiver Quantitative
Cellectar Biosciences (CLRB) Edges Higher Amid Low Volume; Key Support and Resistance in FocusEquity Put Call - dars.gov.et
Cellectar Biosciences (CLRB) Edges Higher as Volume Picks Up at Critical JunctureDark Pool Volume - dars.gov.et
Cellectar Biosciences Inc (CLRB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cellectar Biosciences Inc (CLRB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CLRB|Cellectar Biosciences Inc|Price:2.410|Chg%:-0.060 - TradingKey
Cellectar Biosciences Inc (CLRB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Cellectar Biosciences Inc (CLRB) Balance Sheet - TradingKey
Cellectar Biosciences Inc (CLRB) Cash Flow - TradingKey
CLRB Stock Surged 27% Today – Here’s Why Retail Is Bullish About Cellectar’s Blood Cancer Trial Data - Stocktwits
Cellectar Biosciences (CLRB) Q1 2026 earnings summary - Quartr
Cellectar Biosciences (CLRB) Proxy filing Summary - Quartr
Cellectar Biosciences (CLRB) Q4 2025 earnings summary - Quartr
Cellectar Biosciences (CLRB) Registration filing Summary - Quartr
Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate radiotherapy pipeline, led by iopofosine I-131 in Waldenstrom macroglobulinemia - Bitget
Cellectar Publishes Phase 1 Iopofosine Data - t.co
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers - Sahm
Cellectar publishes phase 1 data on multiple myeloma treatment By Investing.com - Investing.com South Africa
Cellectar Biosciences (CLRB) Announces Positive Phase 1 Study Re - GuruFocus
Cellectar publishes phase 1 data on multiple myeloma treatment - Investing.com
Cellectar Biosciences Announces Publication of Phase 1 Data for Iopofosine I 131 in Relapsed/Refractory Multiple Myeloma - Quiver Quantitative
Cellectar Myeloma Data: 84.6% of 26 Evaluable Patients Stable or Better - Stock Titan
Brookline Capital Initiates Cellectar BioSciences(CLRB.US) With Buy Rating, Announces Target Price $15 - Moomoo
Cellectar Biosciences (CLRB) Stock Fair Value Moves Lower As Analysts Weigh Execution Risk - Yahoo Finance
Form 4 Cellectar Biosciences Inc For: 10 July By Investing.com - Investing.com Nigeria
Form 4 Cellectar Biosciences Inc For: 10 July - Investing.com India
Cellectar Biosciences, Inc. Files Form 8-K: Updated Stock Incentive Plan and Corporate Details for 2026 - Minichart
Cellectar Biosciences (NASDAQ: CLRB) awards 15,000 stock options to consultant - Stock Titan
Cellectar Biosciences (NASDAQ: CLRB) holders approve more stock awards and large warrant exercise - Stock Titan
Form 4 Cellectar Biosciences Inc For: 8 July By Investing.com - Investing.com Nigeria
Cellectar Biosciences (CLRB) CEO awarded 250,000 stock options - Stock Titan
Cellectar (CLRB) awards director Andrew Gu 25,000 options - Stock Titan
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):